“Cytomegalovirus Infections Pipeline” has been added to DelveInsight
Cytomegalovirus Infections Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitors, launch date along with product development activities.
“Cytomegalovirus (CMV) Infection Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cytomegalovirus (CMV) Infection market
Download free sample copy here- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight
Cytomegalovirus Infections Overview
Infection with cytomegalovirus (CMV) is very common. CMV Infections is a type of herpesvirus (herpesvirus type 5). Blood tests show that 60–90% of adults have had a CMV Infections infection at some time.
Cytomegalovirus Infections Key Players
Cytomegalovirus Infections Drugs
Cytomegalovirus Infections Symptoms
CMV Infections may cause symptoms soon after infection and can also remain dormant (inactive) in various tissues for life. Various stimuli can reactivate the dormant CMV Infections, resulting in virus growth which can sometimes cause disease. The lungs, gastrointestinal tract, brain, spinal cord, or eyes may be infected.
Cytomegalovirus Infections Emerging Therapy Assessment
The available therapeutics treatment options in CMV Infection Landscape aim to reduce the disease burden. The current market anticipates the emergence of emerging products namely V160 (Merck), mRNA-1647 (ModernaTX), HB-101/VaxWave (Hookipa Biotech), Triplex (Helocyte), Maribavir (TAK-602)(Takeda/Shire Pharmaceuticals), and Viralym-M (AlloVir).
All the upcoming therapies are either for prevention or treatment. In the emerging prophylactic pipeline, four therapies, i.e., V160, mRNA-1647, HB-101, Triplex are expected to launch, and one, i.e., prevymis is already approved. Whereas, in the therapeutic pipeline, two candidates are there, i.e., Maribavir, and Viralym-M.
Cytomegalovirus Infections Treatment
The available therapeutics treatment options in Chemotherapy-Induced Peripheral Neuropathy Landscape aim to reduce the disease burden. Triplex is a first-in-class, best-in-class, universal (non-HLA-restricted) recombinant modified vaccinia ankara viral vector vaccine engineered to induce a robust and durable virus-specific T cell response to three immuno- dominant proteins linked to CMV complications in the transplant setting: UL83 (pp65), UL123 (IE1) and UL122 (IE2). The drug was developed in partnership with the National Cancer Institute by its lead investigator, Diamond, of City of Hope. In a phase 1 study, Triplex was found to be safe, well-tolerated and highly immunogenic when administered to healthy volunteers.
Cytomegalovirus Infections Pipeline Report
When the infection threatens life or eyesight, an antiviral drug (valganciclovir, ganciclovir, cidofovir, foscarnet, or a combination) may be given. These drugs may be given by mouth or by vein. When CMV Infections retinitis is very severe, the drugs may also be injected directly into the eye. These drugs have serious side effects, which increase the demand and need for more potential therapies.
Cytomegalovirus Infections Report Highlights
Following is the TOC of Cytomegalovirus Infections report
1. Report Introduction
2. Cytomegalovirus (CMV) Infection
3. Cytomegalovirus (CMV) Infection Current Treatment Patterns
4. Cytomegalovirus (CMV) Infection – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cytomegalovirus (CMV) Infection Late Stage Products (Phase-III)
7. Cytomegalovirus (CMV) Infection Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cytomegalovirus (CMV) Infection Discontinued Products
13. Cytomegalovirus (CMV) Infection Product Profiles
14. Cytomegalovirus (CMV) Infection Key Companies
15. Cytomegalovirus (CMV) Infection Key Products
16. Dormant and Discontinued Products
17. Cytomegalovirus (CMV) Infection Unmet Needs
18. Cytomegalovirus (CMV) Infection Future Perspectives
19. Cytomegalovirus (CMV) Infection Analyst Review
20. Appendix
21. Report Methodology
What are the key questions of the report?
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: www.delveinsight.com/